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List of Abbreviations: COIITSS: corticosteroids and intensive insulin therapy for septic 
shock; CRP: C-reactive protein; I-FABP: intestinal fatty acid binding protein; ICU: intensive 
care unit; IL-10 interleukin-10; MOF: multiple organ failure; SD: standard deviation; SAPS: 
simplified acute physiology score; SOFA: sequential organ failure assessment; TNF: tumor 
necrosis factor .
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Abstract 
Purpose: Hypocitrullinemia has been suggested to be a prognostic factor for patients in 
intensive care. The aim of this ancillary study of the Corticosteroids and Intensive Insulin 
Therapy for Septic Shock prospective study was to investigate plasma L-citrulline 
concentrations and its relationship with inflammation and digestive bacterial translocation in 
septic shock multiorgan failure patients, without primary intestinal disease or chronic renal 
failure.  
Methods: Sixteen adult patients were selected. They were studied on day (D) 0 at hours (H) 0, 
6, 12, 18, 24 and on D4 (H96). Selected plasma amino acids and proteins, pro- (TNFα) and 
anti-inflammatory (IL-10) cytokine concentrations, and bacterial translocation were 
measured.  
Results: Eight day-14 survivors and 8 day-14 non-survivors patients were studied. Citrulline 
was decreased during D0 (H0: 29±10 vs. nadir: 18±6 µmol/L, P < 0.05). The citrulline nadir 
was lower (P < 0.01) in patients with digestive bacterial translocation than in those without. 
H0-H96 mean citrulline concentrations were not significantly different between survivors and 
non-survivors. In both groups, citrulline was significantly inversely correlated with CRP 
(r2=0.10, P<0.01) during D0. No significant correlations were found between citrulline and 
albumin, transthyretin, TNFα, IL-10 or TNFα/IL-10 ratio.  
Conclusions: At the onset of septic shock, plasma citrulline decreases and varies inversely 
with CRP and is lower when digestive bacterial translocation occurs. This finding could 
reflect an early acute intestinal dysfunction but measurement of citrulline concentration does 
not appear to be able to predict the patients’ mortality. 
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Introduction 
Acute intestinal dysfunction has been postulated as a cause of systemic inflammatory 
response syndrome and multiple organ failure (MOF) in patients with septic shock in 
intensive care unit (ICU). This “gut hypothesis” is difficult to evaluate, except when gastric 
tonometry identifies intramucosal acidosis, reflecting digestive mucosal ischemia 1, 2. 
Reported prevalence of intestinal dysfunction in ICU ranges from 20% to 60%, depending on 
recruitment and the clinical criteria used, notably food intolerance and (or) intra-abdominal 
hypertension 3. Circulating L-citrulline is a biomarker of enterocyte functional metabolic mass 
and is not difficult  to be determined by ion-exchange chromatography 4.. Indeed, this amino 
acid is synthesized in the enterocytes of intestinal mucosa from glutamine and arginine, and 
is, moreover, not a component of proteins, or included in nutrition products. Plasma citrulline 
has a half-life of 3 hours in normal conditions and is converted to arginine by the proximal 
convoluted kidney tubules 5. These metabolic features explain why plasma citrulline 
concentration (normal values: 30–50 mol/L) is therefore, in the clinical situation, a reliable 
biomarker of gut metabolic mass with a high positive relationship with functional remnant 
length of the small bowel in various intestinal diseases 6, either post-surgical (short bowel 
syndrome) 7 or medical (villous atrophy) 8. In addition, low plasma citrulline has been 
suggested as a risk factor for intestinal bacterial translocation in the context of allogenic bone 
marrow transplantation 9 and is associated with endotoxemia in post-cardiac arrest patients 10. 
Moreover, a low plasma citrulline concentration appears to be an independent risk factor for 
catheter-related bloodstream infections in children with intestinal failure 11. Patients with 
septic shock have been shown to have a marked reduction of citrulline synthesis 12-14. 
However, another study shown conflicting results, with an increase in citrulline synthesis 
compared with control subjects 15. Authors found that hypocitrullinemia below 10 mol/L 
occurs 24 h (H24) after admission to ICU, due to a decreased intestinal production, possibly 
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related to small bowel ischemia 16. In addition, hypocitrullinemia was shown to be an 
independent factor of mortality adding to sequential organ failure assessment (SOFA) 16, an 
index that does not take digestive function into account 17. Another study in ICU patients with 
varied pathologies suggests that low plasma citrulline is associated with intestinal 
dysfunction, similarly to a high residual gastric volume, ileus, diarrhea or gastrointestinal 
bleeding, but not with mortality 18. However, the behavior of citrulline and its relationship 
with metabolic and inflammatory parameters in ICU patients is not known. In this pilot study, 
our aim was to further investigate the presence of an association between  plasma L-citrulline 
concentration,  inflammation and bacterial  translocation Therefore we investigated, in ICU 
patients with severe septic shock and MOF treated with conventional insulin therapy and 
hydrocortisone hemisuccinate: (i) citrulline concentrations over a 4-day period, and (ii) its 
potential relationship with biological nutritional and inflammatory parameters and the 
occurrence of a digestive bacterial translocation.  
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Materials and Methods  
Patient’s inclusion and exclusion criteria 
We performed an ancillary investigation within the multicentre Corticosteroids and Intensive 
Insulin Therapy for Septic Shock (COIITSS) study (trial registration: clinicaltrials.gov 
NCT00320099) 19 in patients recruited between January 2006 and January 2009. The 
COIITSS study protocol was approved by the “Comité de Protection des Personnes de Saint-
Germain-en-Laye” ethical committee on 24th May, 2005. Written informed consent was 
obtained from the patients or their relatives in compliance with the French regulations for 
clinical research in emergency and critical care.  
Patients were included from the conventional insulin therapy arm, in which blood glucose 
levels were maintained at approximately 8.3 mmol/L (150 mg/dL), in accordance with 
recommendations, 20 by the administration of either subcutaneous or intravenous insulin. In 
addition, all patients received hydrocortisone hemisuccinate in a 50 mg intravenous bolus 
every 6 h for 7 days. We selected patients with septic shock and a global baseline SOFA > 8 
(indicating MOF). However, because plasma citrulline increases in significant renal failure 5, 
renal SOFA had to be < 2 (i.e. plasma creatinine < 299 mol/L). Organ system failure was 
defined for each of the six major organ systems as a SOFA score of 3 or 4 points on a scale of 
0–4 for each organ system, for an aggregate score of 0–24, with higher scores indicating more 
severe organ dysfunction 17. We excluded patients with primary intestinal disease, diabetes 
mellitus or chronic renal failure. All the patients presented with septic shock and MOF at 
admission. They received intravenous fluids and vasopressor therapy (dopamine, adrenaline, 
noradrenalin, or any other vasoconstrictor agent) to maintain systolic blood pressure above 
90 mm Hg or mean blood pressure above 60 mm Hg. Patients received enteral nutrition using 
a standard polymeric product by nasogastric tube after Day 1. When parenteral nutrition was 
 7 
used, it was only for a short period with conventional non-glutamine supplemented solutions. 
Neither enteral nor parenteral products contained citrulline. 
Sixteen patients (7 males, 9 females, mean age 61 yrs, Table 1) from the 138 patients 
(including 60 with fatal outcome during the study) of the COIITSS study who were 
randomized to receive conventional insulin therapy with hydrocortisone only 19, were selected 
on the above criteria and studied over a 4-day period. The patients were divided into two 
groups: survivors at day 14 following ICU admission (n = 8), and non-survivors, with time of 
death ranging from day 6 to day 14 (n = 8).  
 
Variables recorded 
Recorded parameters were creatinine, arterial lactates, total bilirubin, CRP, basal cortisol 
concentrations and cortisol concentrations at the peak 1 h after a 250 g intravenous 
corticotropin injection. Severity of illness was determined using the SOFA and SAPS II 
(simplified acute physiology score) scales 21 (Table 1). In addition, specific biological data 
were measured. 
 
Specific assays 
Plasma samples were stored at −80 °C. Before assay, all samples were thawed to room 
temperature and mixed by gentle swirling or inversion. Assays were carried out on D0 
[admission (H0), H6, H12, H18 and H24], and at H96. Arterial blood lactates were measured 
at H0, H24, and H96 only. Sampling was performed in patients with no clinical evidence of 
acute dehydration. Plasma citrulline, glutamine and arginine, respectively the main precursor 
and the main metabolite of citrulline at the whole-body level 5, were measured by automated 
ion exchange chromatography as previously described 4. Plasma was deproteinized (with 
sulfosalicylic acid, 30 mg/mL) and plasma-free amino acid concentrations were determined in 
 8 
the supernatant by ion-exchange chromatography with ninhydrin detection 22 using an 
AminoTac JLC-500V analyzer (Jeol, Tokyo, Japan). The between-run precision for plasma 
citrulline determination had a coefficient of variation of less than 7.5%. The assay laboratory 
is a participant in the European Quality Control scheme, thus guaranteeing the accuracy of the 
amino acid determinations. Thirty healthy subjects, sampled after an overnight fast, served as 
controls. They presented no evidence of metabolic or digestive diseases and had normal body 
mass indexes, serum albumin levels and renal function. Albumin and transthyretin were 
determined by immunonephelemetry using a BNII® (Siemens, Paris, France), CRP (C 
reactive protein) by turbidimetry on a Modular P® (Roche Diagnostics, Meylan, France) and 
lactates by an enzymatic method (Dimension RXL®, Siemens). TNF-α and IL-10 levels were 
measured using a solid-phase chemiluminescent immunometric assay method (TNF-α and IL-
10 Immulite®, Siemens Healthcare Diagnostics Products, UK) using an Immulite 1000® 
System. The TNF/IL-10 ratio was used as an index of proinflammatory/anti-inflammatory 
balance 23.  
 
Digestive bacterial translocation 
Digestive bacterial translocation was defined as highly presumable in 12 out of 16 patients 24. 
It included patients with blood cultures positive for enterobacteria with negative 
microbiological urine analysis (n = 7), spontaneous peritoneal infection (n = 3) or occurrence 
of a new episode of septic shock after remission of the initial episode but with negative blood 
or other sites cultures (n = 2). 
 
Statistical analysis 
Results are expressed as means ± SD. Plasma citrulline and other quantitative parameters 
were compared between the two groups using Student’s t-test, ANOVA with repeated 
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measures, Mann-Whitney in cases of non normality distributions or chi-squared and Fisher 
exact test when appropriate. Pearson or Spearman correlations were performed to test 
associations between plasma citrulline and other biological variables. SPSS software version 
11.5 (SPSS Inc, Chicago, IL) was used for the statistical analysis. Statistical significance was 
set at p < 0.05.  
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Results 
Baseline data 
Clinical, bacteriological and biological data at H0 are given in Table 1. There were no 
differences in baseline clinical, biological and bacteriological parameters (Table 2, 3 and 4) 
between the two groups, survivors and non survivors, with the exception of plasma glutamine 
concentration (Table 3). 
 
Behavior of citrulline over the 4-day study period (Figures 1 A and 1 B) 
Plasma citrulline decreased significantly (P < 0.05) during D0 in 11 of the 16 patients, 
18±6 mol/L at the nadir versus 29±10 mol/L at H0. In 5 patients, citrulline concentration 
did not change significantly during D0. The early decrease in plasma citrulline during D0 
occurred in both groups: in 6 and 5 patients of the survivor and non-survivor groups 
respectively. The plasma citrulline nadir was observed at H6 in 4 patients, H12 in 5, H18 in 1 
and H24 in 1. When the behavior of mean plasma citrulline concentrations in survivor and 
non-survivor patients was considered, there were no significant differences between the two 
groups (Table 3) with the exception of a huge range at H96 in non-survivor patients (Figure 1 
B). Analysis of individual data in the non-survivor group showed two patterns of behavior of 
plasma citrulline at H96: 3 patients developed high plasma citrulline concentrations (> 50 
mol/L, with a maximum of 201 mol/L), whereas the other 5 patients had concentrations 
between 0 and 30 mol/L. In the survivors, plasma citrulline concentration remained between 
10 and 30 mol/L in 6 patients and normalized in 2 patients. 
 
Relationship between plasma citrulline and metabolic, nutritional and inflammatory 
parameters 
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The behavior of the biological parameters tested is given in Tables 3 and 4. Plasma citrulline 
concentration was positively correlated with plasma arginine (r = 0.92, r2 = 0.85, P < 0.0001) 
and glutamine (r = 0.95, r2 = 0.90, P < 0.0001) concentrations in both patient groups. No 
significant correlations were found either between plasma citrulline and albumin, or with 
transthyretin. Plasma citrulline levels measured at baseline correlated with baseline creatinine 
level (r = 0.25, r2 = 0.06, P = 0.04), but the correlation was not significant at H96. A 
significant positive correlation was found between glutamine and lactates at H24 (r = 0.81, r2 
= 0.66, P < 0.01) and H96 (r = 0.79, r2 = 0.62, P < 0.01). In addition, a similar correlation 
between citrulline and lactates was observed at H24 (r = 0.57, r2 = 0.32, P = 0.053) and H96 
(r = 0.80, r2 = 0.64, P < 0.01). At most of the evaluations (H0, H12, H18, H24 and H96), 
plasma glutamine concentrations were significantly lower (P < 0.05) in survivors than in non-
survivors (Table 3). 
In both groups, plasma citrulline concentration was negatively related to CRP at all the 
D0 evaluations (r = −0.31, r2 = 0.10, P = 0.0017) (Figure 2 for H0), but not at H96. No 
significant correlations were found between plasma citrulline and TNF, IL-10 or TNF/IL-
10 ratio. Similarly, no significant correlations were found for glutamine and arginine and 
circulating TNF, IL-10 or TNF/IL-10 ratio, whereas both glutamine and arginine were 
significantly negatively correlated with CRP (r = −0.35, r2 = 0.12, P < 0.001 and r = −0.39, r2 
= 0.15, P < 0.001 respectively). Circulating IL-10 was higher (P < 0.05), especially at H6 and 
H12, in non-survivor than in survivor patients (Table 4). Inflammatory balance estimated by 
TNF/IL-10 ratio was significantly higher (ANOVA, P < 0.05) in survivor than in non-
survivor patients (Table 4), however the only time for significant differences between the 
groups was H12.  
 
Citrulline and digestive bacterial translocation 
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The nadir of plasma citrulline, which occurred during D0 in all cases, was significantly lower 
(P < 0.01) in patients with presumable translocation than without (Table 5). All the patients 
with a plasma citrulline nadir below 10 mol/L (n = 4) had presumable bacterial 
translocation. There were no significant differences between patients with or without 
digestive bacterial translocation for the other biological parameters tested at the time of the 
citrulline nadir, including TNF and IL-10 and its ratio (Table 4).  
 13 
Discussion 
In a group of ICU patients with septic shock treated with conventional insulin therapy and 
hydrocortisone hemisuccinate, plasma citrulline concentrations decreased during D0 in the 
majority of patients. An important finding in this study is that patients with the lowest 
citrulline nadir had the highest risk of digestive translocation, confirming results observed in 
studies of allogenic bone marrow transplantation 9 and cardiac arrest for endotoxemia 10. 
However, bacterial translocation was estimated by an indirect approach because we had no 
access to mesenteric lymph node cultures. In addition, for some patients, pneumonia 
following microaspiration of gastric fluid containing Gram-negative bacteria could cause an 
overestimation of bacterial translocation. Nevertheless the role of inflammation on citrulline 
level is difficult to appraise. The negative relationship with CRP suggests a role of 
inflammation in altered citrulline metabolism, but without a direct role of TNF and IL-10. 
The results did not show any significant relationship between plasma citrulline and pro-
inflammatory cytokines (TNF), anti-inflammatory cytokines (IL-10) or inflammatory 
balance estimated by the TNF/IL-10 ratio. However, a negative correlation was confirmed 
between citrulline and CRP, at least on D0, as has previously been found in critically ill 
children 25. In another ICU study, no such relationship was found 18. The difference in 
behavior between the cytokines under study and CRP may be explained by the fact that CRP 
production is mostly controlled by IL-6 but this latter cytokine was not measured. In an 
experimental rat model of sepsis, citrulline supplementation decrease IL-6 response but have 
no effect on IL-10 secretion 26. Although mean plasma citrulline was not significantly 
different between survivors and non-survivors in this small group of patients, our results show 
that citrulline levels may normalize at H96 in patients with the best prognosis. It would be 
interesting to have citrulline data after a more prolonged period. Our results did not show any 
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relationship between citrulline level and prognosis, but this may be due to the limited power 
of this study. 
Two limitations of this study are the small number of patients and the absence of 
direct intestinal evaluation. Although the results may thus not be representative of the overall 
ICU patient population, they may nevertheless be representative of patients with severe septic 
shock. These patients are characteristically unstable, which may explain the heterogeneity of 
some of the results. In a previous study of 65 patients, the decrease in citrulline at H24 was 
more marked in patients with septic shock than in those who did not have septic shock 16. In 
our study, citrulline behavior was not clearly related to renal impairment. The results showed 
that there was no correlation between H96 plasma creatinine and citrulline in patients with a 
baseline renal SOFA < 2, confirming previous data in ICU patients with acute renal failure 16, 
18
. However, this key point deserves further specific study.  
Possible explanations for the variations and changes in citrulline levels may be related 
to tissue and (or) metabolic parameters. It is known that hypocitrullinemia is always due to a 
decreased intestinal production 4. In the present study, an impairment of intestinal function for 
example secondary to mucosal intestinal ischemia, could be a possible explanation 27, 28. 
Hence, the results found during D0 could reflect an acute intestinal dysfunction in some ICU 
patients with septic shock; however citrulline, as a surrogate marker, only gives an indirect 
intestinal evaluation. To our knowledge, there is currently only one ICU study that focuses on 
the relationship between citrulline level and digestive symptoms 18 but it does not report on 
the relationship between citrulline and intestinal lesions. On the other hand, it is known that 
the decrease in citrulline cannot be contemporaneously related to clinical symptoms, due to 
the fast decrease in plasma citrulline and the possible adaptation of the digestive tract as 
shown in acute radiation enteritis 29. In addition, enteral nutrition or other modes of nutrition 
seems do not influence plasma citrulline in ICU patients18.. As expected, we found a strong 
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correlation between plasma citrulline and its major precursor (glutamine) and major 
metabolite (arginine). A metabolic cause of hypocitrullinemia, notably by a decrease in its 
main precursor, glutamine, cannot be excluded14, but a purely metabolic explanation is 
unlikely. In our study, plasma glutamine was significantly lower in survivor patients as has 
previously been shown in some stressed patients during the first day of admission to ICU 30. 
On the other hand, a study with stable isotope tracers including [5,5-2H2]citrulline in patients 
with sepsis (n = 8) or septic shock (n = 5) showed a reduction in citrulline flux and citrulline 
and arginine concentrations, with, in consequence, an insufficient arginine synthesis 12. This 
was also shown in another isotopic study of patients with septic shock, in whom a decrease in 
nitric oxide (NO) production was also suggested 13. In contrast, an increase in citrulline flux 
and NO production, calculated as the conversion rate of arginine to citrulline has been 
observed in critically ill children with sepsis 15... This could question the relevance of 
citrulline as a surrogate intestinal biomarker as compared to other test like I-FABP (intestinal 
fatty acid binding protein) assay 31. Circulating I-FABP increases during the acute phase of 
sepsis, is associated with a worse 28-day prognosis 31 and has been considered as a marker of 
enterocyte damage in ICU 32.  
 
Conclusions 
A major decrease in plasma L-citrulline can occur in ICU patients with septic shock, 
additionally associated with digestive bacterial translocation and increased CRP. However, in 
this pilot study, we were unable either to assert or to deny the prognostic value of plasma 
citrulline, based on its concentrations in patients with poor prognoses. Meanwhile, the 
influence of intestinal perfusion, hemodynamic instability and metabolic and hormonal 
management on citrulline level in this context remains to be more precisely determined. In 
addition, a more powerful and larger study is needed, for example using the citrulline 
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generation test (stimulation of citrulline production with enteral glutamine) 33, in order to 
examine more closely the behavior of plasma citrulline found in this study.  
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Table 1. Baseline (H0) clinical, bacteriological and biological (plasma concentration) 
characteristics of the 16 septic shock patients 
 
Characteristics  
Age (years) 61±18 
Sex: male/female (n) 7/9 
Creatinine (mol/L) 136.2±82 
Bilirubin (mol/L) 69±72 
SOFA  11.9±3.0 
SAPS II 58±16.2 
Albumin (g/L) 17.8±6.4 
Sites of infection (n) 26 sites 
    Chest 17 
    Peritoneal 5 
    Urogenital 1 
    Septicemia 3 
    Wound 1 
    Central nervous system 1 
Pathogens, Gram-negative (n) 9 (56%) 
Presumable digestive bacterial 
translocation (n) 
12 
Citrulline (N: 30–50 μmol/L) 
Glutamine (N: 480–670 μmol/L) 
Arginine (N: 60–80 μmol/L) 
23±13 
489±328 
44±42 
CRP (N < 5 ng/mL) 
TNF alpha ฀ (N < 8.1 pg/mL฀ ) 
IL-10 (N < 9.1 pg/mL) 
TNF ฀alpha/IL-10 ratio 
Lactates (N < 2.4 mmol/L) 
167±14 
37 (4-895) 
19 (4-1000) 
1.8 (0.21-223) 
11±23 
 
Values are mean±SD, median (range) for TNF alpha, IL-10 and TNF alpha/IL-10 ratio or 
quantitative number (n) 
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Table 2. Baseline (H0) and bacteriological characteristics of the two groups of septic shock 
patients 
 
Characteristics Survivors (n = 8) Non-survivors (n = 8) 
Age (years) 60 (±16.5) 62.9 (±18.5) 
Sex: male/female (n) 3/5 4/4 
Creatinine (mol/L) 145.4 (±105.1) 132.1 (±77.3) 
Arterial lactates (mmol/L) 16.7 (±34.9) 7.8 (±6.0) 
Bilirubin (mol/L) 71 (±83) 66 (±63) 
Prothrombin ratio (%)1 43 (±19) 47 (±24) 
SOFA  11.75 (±2.5) 12.4 (±4.5) 
SAPS II 56 (±20.8) 62.1 (±14.5) 
CRP (mg/L) 169 (±83) 164 (±144) 
Albumin (g/L) 18.4 (±4.9) 17 (±7.9) 
Cortisol levels (g/dL)    
   Basal 25.7 (±14.9) 41.1 (±33.8) 
   Peak 25.8 (±17.5) 44.5 (±30.9) 
Sites of infection (n) 12 sites 16 sites 
    Chest 6 11 
    Peritoneal 4 1 
    Urogenital 0 1 
    Septicemia 1 2 
    Wound 1 0 
    Central nervous system 0 1 
Pathogens, Gram-negative (n) 4 (50%) 5 (62.5%) 
Presumable digestive bacterial 
translocation (n) 6 6 
 
1
 Value at H24 
Values are mean (±SD) or quantitative number (n) 
None of the characteristics were significantly different between the 2 groups (Chi 2 for 
qualitative data and t-test for quantitative data). 
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Table 3. Plasma citrulline, glutamine, and arginine over the study period 
Plasma level (mean, SD) H 0 H 6 H 12 
 Survivors Non-survivors Survivors Non-survivors Survivors Non-survivors 
  Citrulline (N: 30–50 μmol/L) 
  Glutamine (N: 480–670 μmol/L)* 
  Arginine (N: 60–80 μmol/L) 
23 (12) 
381 (69)** 
37 (44) 
24 (15) 
598 (418)** 
53 (41) 
25 (15) 
424 (256) 
49 (55) 
20 (16) 
528 (280) 
39 (33) 
19 (12) 
316 (166)** 
44 (44) 
20 (13) 
562 (366)** 
49 (47) 
  
 
 
 
 
 
 H 18 H 24 H 96 
 Survivors Non-survivors Survivors Non-survivors Survivors Non-survivors 
  Citrulline 
  Glutamine* 
  Arginine 
21 (12) 
335 (129)** 
46 (40) 
29 (32) 
656 (493)** 
62 (48) 
22 (12) 
335 (129)** 
53 (38) 
29 (18) 
621 (312)** 
93 (48) 
24 (8) 
427 (157)** 
89 (45) 
76 (76) 
1224 (1037)** 
174 (152) 
Values are mean (SD). * P < 0.05 (repeated measures ANOVA) between survivors and non-survivors, and P <0.05 ** at different times. 
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Table 4: Plasma CRP, cytokines (TNFandIL-10 and lactates over the study period 
Plasma level H 0 H 6 H 12 
 Survivors Non-survivors Survivors Non-survivors Survivors Non-survivors 
  CRP (N < 5 ng/mL) 
  TNF alpha (N < 8.1 pg/mL) 
  IL-10 (N < 9.1 pg/mL)* 
  TNF alpha/IL-10 ratio* 
  Lactates (N < 2.4 mmol/L) 
169 (83) 
32 (4–895) 
12 (4–400) 
3.13 (0.21–223) 
16 (35) 
164 (144) 
42 (14–306) 
20 (4–1000) 
1.7 (0.3–11.8) 
7.8 (6) 
206 (110) 
27 (3–1100) 
6 (4–253)** 
3.47 (0.18–275) 
 
158 (110) 
68 (14–212) 
89 (12–718)** 
0.65 (0.21–3) 
 
200 (132) 
27 (6–1100) 
5 (4–73)** 
2.6 (0.38–275)** 
 
152 (108) 
56 (14-138) 
102 (9-311)** 
0.82 (0.2-4.1)** 
 
  
 
 
 
 
 
 H 18 H 24 H 96 
 Survivors Non-survivors Survivors Non-survivors Survivors Non-survivors 
  CRP 
  TNF alpha 
  IL-10 * 
  TNFalpha/IL-10 ratio* 
  Lactates  
203 (135) 
24 (6–810) 
10 (4–70) 
2.37 (0.27–72) 
 
133 (110) 
46 (14–102) 
39 (9–171) 
1.35 (0.32–3.77) 
 
190 (145) 
24 (4–627) 
8 (4–67) 
2.49 (0.2–156) 
2.6 (1.7) 
75 (21) 
49 (14–72) 
47 (14–104) 
1.01 (0.47–.54) 
7.4 (7.5) 
84 (103) 
22 (4–569) 
4 (4–188) 
1.95 (0.09–42) 
2.3 (1.8) 
84 (98) 
37 (32-47) 
17 (7.5-24) 
2.78 (1.4-4.3) 
3.8 (3) 
Values are mean (SD) for CRP and lactates and median (range) for TNF alpha, IL-10 and TNF alpha/IL-10 ratio. 
* P < 0.05 (repeated measures ANOVA; non parametric tests for cytokines) between survivors and non-survivors, and P <0.05 ** at different 
times. 
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Table 5. Citrulline at nadir (D0) with other biological parameters collected at the same time, 
and bacterial digestive translocation 
 
 
 
 
Translocation 
(n = 12) 
No translocation 
(n = 4) 
Plasma citrulline nadir (mol/L) 
 
13±6* 
 
29±7 
 
Glutamine (mol/L) 
Arginine (mol/L) 
CRP (ng/ml) 
TNFpg/mL) 
IL-10 (pg/mL) 
TNF/IL-10 
Albumin (g/L) 
Transthyretin (g/L) 
330±208 
31±27 
189±129 
42 (3–1100) 
16 (4–718) 
1.7 (0.29–275) 
19±8 
0.11±10 
496±184 
57±58 
110±103 
28 (21–69) 
56 (4–311) 
0.38 (0.22–15) 
16±2 
0.05±0.01 
Values are mean ± SD or median (range) 
*P < 0.01 between translocation and no translocation 
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Figure: 
 
Figure 1 A. Behavior of plasma citrulline concentration in the 8 septic shock survivor patients 
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Figure 1 B. Behavior of plasma citrulline concentration in the 8 septic shock non survivor 
patients 
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Individual time course and median value at each time. Outliers are not on the Figure. 
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Figure 2. Relationship between plasma citrulline and CRP concentrations at H0 in survivor 
(n=8) and non-survivor (n=8) septic shock patients 
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r = - 0.77, r2=0.593 
P<0.001 
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